ERFURT and BERLIN, Germany,
April 7, 2021 /CNW/ - AMP Alternative
Medical Products Inc. (Frankfurt: C4TA) (ISIN: CA0318961038) (CSE:
XCX), a pharmaceutical supplier of medical cannabis to German
pharmacies, announces the appointment of Mr. Robert Schenk as National Sales Director and the
launch of AMP's nationwide Marketing Sales Campaign for branded
medical cannabis products.
Mr. Schenk, who will oversee the development and execution of
AMP's sales and marketing strategies and lead our nationwide sales
team, officially joins AMP today. Mr. Schenk brings over 20 years
of experience in the pharmaceutical industry to AMP and was most
recently, Regional Manager of Canopy Growth Germany GmbH, a
subsidiary of Canopy Growth Corporation (Nasdaq: CGC), where he
established, built and lead Canopy's nationwide sales team in
Germany.
AMP also launched its marketing sales campaign for AMP's line of
branded medical cannabis products, which includes cannabis flower
products: Aphria Strong 9, Bedrocan and Bediol Cannabis Floss,
as well as extracts: Little Green Pharma Classic 20:5 and
Classic 10:10. AMP will be launching its cannabis flower product
AMP Classic 18/1 Primary in May 2021
supplied by Schroll Medical and additional AMP branded flower
and extract products from Canada
as well as Australia during the
second half of the year. German doctors and pharmacists can find
further information about AMP's medical cannabis products at
www.amp-eu.com/doccheck-login/.
AMP's nationwide sales team includes highly capable and
accomplished pharmaceutical sales representatives in Stade,
Cologne, Nordhausen and Speyer who are selling Aphria
and AMP's catalogue of medical cannabis products to over 13,000
pharmacies under AMP's co-promotion agreement with CC Pharma, a
national pharmaceutical distributor and a wholly-owned subsidiary
of Aphria Inc. (Nasdaq: APHA).
Photo: AMP's management and sales team. You can view this photo
at: https://twitter.com/AMP_Cannabis/status/1379631320956071936
AMP and CC Pharma are jointly training their sales teams on how
to advance knowledge among doctors and best practices
fulfilling medical cannabis prescriptions and how medical
cannabis can help in patient therapy and ensuring that pharmacies
nationwide have access to AMP's selection of medical cannabis
products.
To advance the benefits of medical cannabis therapy
knowledge, AMP and CC Pharma are holding education seminars across
Germany for doctors and
pharmacists.
AMP also launched its new website (www.amp-eu.com) which
provides information about medical cannabis and a secure portal for
doctors and pharmacists for information about our products and how
to contact our sales team.
Dr. Stefan Feuerstein, President
and Director of AMP, commented, "Our strategy is to focus on
servicing our customers and commit to advance medical cannabis
therapy for the patient. AMP and CC Pharma are committed to this
strategy and are advancing education about the health benefits of
cannabis and best practices for patient therapy in the medical
community through our joint education seminars for doctors and
pharmacists".
Robert Schenk, National Sales
Director of AMP, commented, "AMP has been able to assemble a wide
range of leading medical cannabis flower and extract brands
products for sale during challenging times during the Corona
pandemic. Our nationwide sales team has been trained to help
educate doctors about the benefits of medical cannabis in patient
therapy."
About AMP
AMP Alternative Medical Products Inc. (formerly AMP German
Cannabis Group Inc.) is a pharmaceutical narcotic supplier of
medical cannabis to German pharmacies with offices in Erfurt and
Berlin, Germany. AMP
operates in accordance with the German Narcotic Drug Act (BtMG) and
with the Free State of Thuringia, ensuring medical cannabis
products imported by AMP from around the world and sold in
Germany meets the European Union -
Good Manufacturing Practice (EU-GMP) standard. AMP's nationwide
sales team represent medical cannabis product brands from Aphria,
Bedrocan and Little Green Pharma. Learn more
at www.amp-eu.com.
The AMP Roundtable Series discusses issues about medical
cannabis in Germany and is
available as a podcast and video. In Episode #2, "Politics and
Medical Cannabis in Germany" Dr.
Wieland Schinnenburg, MdB (FDP), provides an up-to-date overview of
the political issues and challenges facing the medical cannabis
industry in Germany. Learn more at
www.amp-eu.de/roundtable.
Neither the CSE nor its Regulation Services Provider (as that
term is defined in the policies of the CSE) accept responsibility
for the adequacy or accuracy of this release.
This news release contains forward-looking statements that
are based on the Company's expectations, estimates and projections
regarding its business and the economic environment in which it
operates, including with respect to its business plans and
milestones and the timing thereof. Although the Company believes
the expectations expressed in such forward-looking statements are
based on reasonable assumptions, such statements are not
guaranteeing of future performance and involve risks and
uncertainties that are difficult to control or predict. Therefore,
actual outcomes and results may differ materially from those
expressed in these forward-looking statements and readers should
not place undue reliance on such statements. These forward-looking
statements speak only as of the date on which they are made, and
the Company undertakes no obligation to update them publicly to
reflect new information or the occurrence of future events or
circumstances unless otherwise required to do so by law.
SOURCE AMP Alternative Medical Products
